By Ben Glickman
Doximity lifted its full-year outlook for revenue and adjusted earnings before interest, taxes, depreciation and amortization with fiscal second-quarter results. The digital medical platform also authorized up to $70 million in share buybacks over the next year. Shares rise 20% to $24.59 after-hours.
Illumina is expecting its core revenue to sink this year, compared with prior expectations of flat year-on-year revenue, as the company faces challenging macro conditions. The gene-sequencing company also now projects a steeper loss on the year despite its quarterly loss narrowing in the third quarter. Illumina shares drop 8.6% to $97.81 after-hours.
Groupon Interim Chief Dusan Senkypl says the company didn’t make as much progress on key projects as expected in the third quarter and the business “continues to be challenged.” The company reinstates guidance for the fourth quarter and says it expects a drop in revenue of 7% to 14%. Shares tumble 36% to $8.69 after-hours.
Write to Ben Glickman at [email protected]
Read the full article here
